Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
1552.6(c) 1563.6(c) 1553.2(c) 1576.6(c) 1576(c) Last
5 139 905 7 734 447 6 306 255 8 863 742 7 518 971 Volume
+0.31% +0.71% -0.67% +1.51% -0.04% Change
More quotes
Financials (GBP)
Sales 2018 30 182 M
EBIT 2018 8 084 M
Net income 2018 3 844 M
Debt 2018 20 764 M
Yield 2018 5,08%
Sales 2019 30 881 M
EBIT 2019 8 331 M
Net income 2019 4 382 M
Debt 2019 19 209 M
Yield 2019 5,12%
P/E ratio 2018 21,52
P/E ratio 2019 17,71
EV / Sales2018 3,28x
EV / Sales2019 3,15x
Capitalization 78 168 M
More Financials
Company
GlaxoSmithKline Plc is a global healthcare company which engages in developing, manufacturing, and marketing of pharmaceutical products including vaccines, over the counter medicines and health-related consumer products.It operates through the following segments: Pharmaceuticals, Pharmaceuticals... 
Sector
Pharmaceuticals
Calendar
07/25 | 12:00pmEarnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
07/14GLAXOSMITHKLINE : James Ford Appointed GSK General Counsel
AQ
07/12GLAXOSMITHKLINE : US FDA Advisory Committee endorses the effectiveness and safet..
PU
07/12GLAXOSMITHKLINE : Recent Studies from GlaxoSmithKline plc Add New Data to Conjug..
AQ
07/12GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Provide Details of New St..
AQ
07/12GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Report New Studies and Fi..
AQ
07/12GLAXOSMITHKLINE : Sells Tapinarof Rights for Up to GBP250 Million
DJ
07/12GLAXOSMITHKLINE : James Ford appointed GSK General Counsel
PU
07/12GLAXOSMITHKLINE : Roivant subsidiary Dermavant Sciences signs agreement with GSK..
PU
07/09GLAXOSMITHKLINE : Health and Human Services Department (HHS); Food and Drug Admi..
AQ
07/06TRAVELERS VACCINES MARKET CHALLENGES : QY Reports added Most up-to-date research..
AQ
More news
Sector news : Pharmaceuticals - NEC
07/14INDIVIOR : wins preliminary injunction against generic rival
RE
07/13TEVA PHARMACEUTICAL INDUSTRIES : FDA Recalls Several Medicines That Contain Vals..
DJ
07/13NOVARTIS : Played Down Ties to Trump Lawyer Michael Cohen, Report Says
DJ
07/13JOHNSON & JOHNSON : J&J vows to overturn $4.7 billion talc verdict but experts s..
RE
07/13NOVARTIS : disputes U.S. senators' report on Cohen contract
RE
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on GLAXOSMITHKLINE 
GLAXOSMITHKLINE  - 2015
This could be the time to buy
BUY
GLAXOSMITHKLINE - 2014
Bearish signal below GBp 1415
SELL
More Strategies
Latest Tweets
07/15Zacks: Analysts Expect Theravance Biopharma Inc $TBPH Will Announce Earnings .. 
07/13Analysts Anticipate Theravance Biopharma Inc $TBPH Will Post Quarterly Sales .. 
07/13$GSK: GlaxoSmithKline announces the US FDA Advisory Committee endorsed the ef.. 
07/13Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug: A new CSO i.. 
07/12GlaxoSmithKline : US FDA Advisory Committee endorses the effectiveness and sa.. 
More tweets
Qtime:273
News from SeekingAlpha
07/15YOUR DAILY PHARMA SCOOP : Zogenix Zooms, Zynerba's Changing Fortunes, AbbVie Pro.. 
07/12Ad Com thumbs up on Glaxo's malaria drug tafenoquine; shares up 1.5% 
07/12Drug prices still marching upward - Bloomberg 
07/11Big Pharma in the red after Pfizer backs away from price hikes 
07/10Pricing transparency law in California having effect, drug makers nix planned.. 
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 15,9  GBP
Spread / Average Target 0,66%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE19.17%103 431
JOHNSON & JOHNSON-8.56%337 763
PFIZER3.59%219 534
NOVARTIS-3.93%201 464
ROCHE HOLDING LTD.-5.60%200 973
MERCK AND COMPANY11.76%169 193